Promise and pitfalls of quantitative imaging in oncology clinical trials.

[1]  Paul E Kinahan,et al.  Quantitative assessment of dynamic PET imaging data in cancer imaging. , 2012, Magnetic resonance imaging.

[2]  R. Passariello,et al.  Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR). , 2012, Urologic oncology.

[3]  Qing Ji,et al.  Dynamic contrast‐enhanced magnetic resonance imaging as a prognostic factor in predicting event‐free and overall survival in pediatric patients with osteosarcoma , 2012, Cancer.

[4]  S. Dry,et al.  3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma , 2012, Cancer.

[5]  P. Choyke,et al.  11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation , 2012, The Journal of Nuclear Medicine.

[6]  Paul Kinahan,et al.  Design considerations for using PET as a response measure in single site and multicenter clinical trials. , 2012, Academic radiology.

[7]  P. Casali,et al.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  T. Cloughesy,et al.  3′-Deoxy-3′-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab , 2012, The Journal of Nuclear Medicine.

[9]  Haesun Choi.  Imaging modalities of gastrointestinal stromal tumors , 2011, Journal of surgical oncology.

[10]  R. Boellaard.  Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments , 2011, The Journal of Nuclear Medicine.

[11]  A. Padhani.  Integrating multiparametric prostate MRI into clinical practice , 2011, Cancer imaging : the official publication of the International Cancer Imaging Society.

[12]  Dong Ho Kim,et al.  Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience , 2011, Cancer research and treatment : official journal of Korean Cancer Association.

[13]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[14]  Daniel L Rubin,et al.  Current and Future Trends in Imaging Informatics for Oncology , 2011, Cancer journal.

[15]  N. Hylton,et al.  MRI in breast cancer therapy monitoring , 2011, NMR in biomedicine.

[16]  S. Larson,et al.  Developing imaging strategies for castration resistant prostate cancer , 2011, Acta oncologica.

[17]  C. Springer,et al.  Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation of preoperative therapy for extremity soft tissue sarcomas (STS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Bruno De Man,et al.  Ultra-low dose CT attenuation correction for PET/CT , 2011, Physics in medicine and biology.

[19]  Thomas Hambrock,et al.  Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. , 2011, Radiology.

[20]  A Gregory Sorensen,et al.  Diffusion and diffusion tensor imaging in brain cancer. , 2011, Seminars in radiation oncology.

[21]  Cynthia H McCollough,et al.  Managing radiation use in medical imaging: a multifaceted challenge. , 2011, Radiology.

[22]  D. Mankoff,et al.  C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases: Relative Findings and Response to Therapy , 2011, Clinical nuclear medicine.

[23]  D. Mankoff,et al.  PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake , 2011, Clinical Cancer Research.

[24]  S. Verma,et al.  Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.

[25]  R. Domingues,et al.  Diffusion MR imaging: an important tool in the assessment of brain tumors. , 2011, Neuroimaging clinics of North America.

[26]  Baris Turkbey,et al.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.

[27]  H. Jadvar.  Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.

[28]  D. Mankoff,et al.  Breast Cancer and Hormonal Stimulation: Is Glycolysis the First Sign of Response? , 2010, The Journal of Nuclear Medicine.

[29]  Radiology,et al.  Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation , 2010 .

[30]  Heinrich Lanfermann,et al.  Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas , 2010, The Lancet Neurology.

[31]  Tracy A Jaffe,et al.  Quantitative imaging in oncology patients: Part 1, radiology practice patterns at major U.S. cancer centers. , 2010, AJR. American journal of roentgenology.

[32]  William Pao,et al.  A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development , 2010, Clinical Cancer Research.

[33]  D. Sargent,et al.  Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.

[34]  D. Mankoff,et al.  Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer , 2010, Clinical Cancer Research.

[35]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Passariello,et al.  459 DETERMINATION OF THE TIME FOR MAXIMAL RESPONSE TO NEOADJUVANT HORMONE THERAPY (LEUPROLIDE) FOR PROSTATE CANCER USING MAGNETIC RESONANCE WITH SPECTROSCOPY (MRSI) AND DYNAMIC CONTRAST ENHANCEMENT (DCEMR) , 2010 .

[37]  J. Machan,et al.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. , 2010, AJR. American journal of roentgenology.

[38]  Alexandre Vignaud,et al.  Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma , 2010, European Radiology.

[39]  Lawrence D. True,et al.  Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.

[40]  Kazuro Sugimura,et al.  Prostate cancer detection with 3 T MRI: Comparison of diffusion‐weighted imaging and dynamic contrast‐enhanced MRI in combination with T2‐weighted imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[41]  D. Dearnaley,et al.  A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. , 2009, European urology.

[42]  R. Simon,et al.  A Comparison of Phase II Study Strategies , 2009, Clinical Cancer Research.

[43]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[44]  Michael J Paldino,et al.  Fundamentals of quantitative dynamic contrast-enhanced MR imaging. , 2009, Magnetic resonance imaging clinics of North America.

[45]  J. Buatti,et al.  Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. , 2009, International journal of radiation oncology, biology, physics.

[46]  Timothy D Johnson,et al.  The parametric response map is an imaging biomarker for early cancer treatment outcome , 2009, Nature Medicine.

[47]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[48]  R. Hicks.  Role of 18F-FDG PET in Assessment of Response in Non–Small Cell Lung Cancer , 2009, Journal of Nuclear Medicine.

[49]  M. Wyss,et al.  Early metabolic responses in temozolomide treated low-grade glioma patients , 2009, Journal of Neuro-Oncology.

[50]  Michael E Phelps,et al.  FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas , 2009, Clinical Cancer Research.

[51]  Sui Shen,et al.  MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan , 2009, Journal of Nuclear Medicine.

[52]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[53]  Janet F. Eary,et al.  NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies , 2009, Molecular Imaging and Biology.

[54]  S. Goodman,et al.  Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  Winfried Brenner,et al.  Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Julie R. Gralow,et al.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  W. Oyen,et al.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  Antje Hoering,et al.  Randomized Phase III Clinical Trial Designs for Targeted Agents , 2008, Clinical Cancer Research.

[59]  Timothy D Johnson,et al.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  W. Huda,et al.  Effective doses in radiology and diagnostic nuclear medicine: a catalog. , 2008, Radiology.

[61]  F. O’Sullivan,et al.  Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival , 2008, Clinical Cancer Research.

[62]  Michael E. Phelps,et al.  Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas , 2008, Clinical Cancer Research.

[63]  Abass Alavi,et al.  Impact of dual-time-point 18F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[69]  D. Vera,et al.  Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET , 2007, Nuclear medicine communications.

[70]  A. Alavi,et al.  Standardized Uptake Values of Normal Breast Tissue with 2-Deoxy-2-[F-18]Fluoro-d-glucose Positron Emission Tomography: Variations with Age, Breast Density, and Menopausal Status , 2006, Molecular Imaging and Biology.

[71]  David M Dilts,et al.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Mostafa Atri,et al.  New technologies and directed agents for applications of cancer imaging. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. Mankoff,et al.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  J. Eary,et al.  [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Ezekiel J Emanuel,et al.  Undue Inducement: Nonsense on Stilts? , 2005, The American journal of bioethics : AJOB.

[77]  M. Baccarani,et al.  Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation , 2005, Nuclear medicine communications.

[78]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  Thomas Beyer,et al.  Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  J. Eary,et al.  Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy , 2005, Cancer.

[81]  D. Yee,et al.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. , 2004, Radiology.

[82]  Adriaan A. Lammertsma,et al.  Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[83]  D. Owens,et al.  Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer , 2003, Annals of Internal Medicine.

[84]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Paul A Meyers,et al.  Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. , 2003, Radiology.

[86]  K. Herholz,et al.  Monitoring the Effect of Chemotherapy in a Mixed Glioma by C‐11‐Methionine PET , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[87]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[88]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[89]  J. Eary,et al.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography , 2002, Cancer.

[90]  David Verbel,et al.  Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. , 2002, Urology.

[91]  Stephen R Thomas,et al.  MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[92]  M. Welch,et al.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  S. Ferrari,et al.  Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  P. Schonken,et al.  Health effects of exposure to low levels of ionizing radiation , 1991 .

[96]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[98]  Richard Simon,et al.  Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. , 2010, Personalized medicine.

[99]  C Gatsonis,et al.  Validation of novel imaging methodologies for use as cancer clinical trial end-points. , 2009, European journal of cancer.

[100]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[101]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[102]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.

[103]  D. Podoloff,et al.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  W. McGuire,et al.  Breast Cancer 4 , 1981, Springer US.